Approach to the Patient With Prolactinoma

Area of Science:

• Endocrinology
• Oncology
• Reproductive Medicine

Background:

• Prolactinomas are the most frequent pituitary tumors, affecting women (microprolactinomas) and men (macroprolactinomas) differently.
• Hyperprolactinemia from prolactinomas is a leading cause of hypogonadotropic hypogonadism, impacting fertility and causing symptoms like osteoporosis and impotence.
• Mass effect symptoms, including hypopituitarism and visual disturbances, are more common in men with macroprolactinomas.

Approach:

• Diagnosis involves prolactin measurement and pituitary imaging, with awareness of potential diagnostic challenges like the hook effect and macroprolactin.
• Dopamine agonists, primarily cabergoline, are the first-line treatment, achieving disease control, restoring fertility, and potentially offering a cure.
• Management strategies are tailored to tumor size, patient sex, and response to therapy, considering pregnancy and menopause as factors for treatment adjustment.

Key Points:

• Cabergoline effectively treats prolactinomas, restoring fertility and potentially leading to cure in one-third of patients.
• Spontaneous prolactin decline during pregnancy or menopause may allow for cabergoline discontinuation in women.
• Treatment resistance in aggressive tumors may necessitate surgery, radiotherapy, or novel agents like temozolomide.

Conclusions:

• Prolactinomas require a multifaceted management approach, balancing medical, surgical, and radiotherapeutic options.
• Emerging therapies show promise for refractory or aggressive prolactinomas, though clinical experience is limited.
• This review provides insights into managing prolactinomas in common clinical scenarios, emphasizing personalized treatment strategies.